These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 29563144)
1. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Waldman SA; Camilleri M Gut; 2018 Aug; 67(8):1543-1552. PubMed ID: 29563144 [TBL] [Abstract][Full Text] [Related]
2. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Jarmuż A; Zielińska M; Storr M; Fichna J Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Miner PB Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436 [TBL] [Abstract][Full Text] [Related]
5. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog. Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122 [TBL] [Abstract][Full Text] [Related]
6. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540 [TBL] [Abstract][Full Text] [Related]
7. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829 [TBL] [Abstract][Full Text] [Related]
8. Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology. Uranga JA; Castro M; Abalo R Curr Med Chem; 2018; 25(16):1879-1908. PubMed ID: 29210639 [TBL] [Abstract][Full Text] [Related]
10. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Forte LR Regul Pept; 1999 May; 81(1-3):25-39. PubMed ID: 10395405 [TBL] [Abstract][Full Text] [Related]
11. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome. Love BL Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753 [TBL] [Abstract][Full Text] [Related]
12. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. Sharma S; Sharma T; Dhingra R; Tomar P; Singh S; Malhotra M; Bhardwaj TR Mini Rev Med Chem; 2013 Oct; 13(11):1685-90. PubMed ID: 24001336 [TBL] [Abstract][Full Text] [Related]
13. Guanylin peptides: cyclic GMP signaling mechanisms. Forte LR; Freeman RH; Krause WJ; London RM Braz J Med Biol Res; 1999 Nov; 32(11):1329-36. PubMed ID: 10559833 [TBL] [Abstract][Full Text] [Related]
14. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain. Hannig G; Tchernychev B; Kurtz CB; Bryant AP; Currie MG; Silos-Santiago I Front Mol Neurosci; 2014; 7():31. PubMed ID: 24795564 [TBL] [Abstract][Full Text] [Related]
15. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587 [TBL] [Abstract][Full Text] [Related]
16. The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. Mishra V; Sharma K; Bose A; Maisonneuve P; Visweswariah SS J Biol Chem; 2024 Jan; 300(1):105505. PubMed ID: 38029963 [TBL] [Abstract][Full Text] [Related]
17. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux. Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Pitari GM Drug Des Devel Ther; 2013; 7():351-60. PubMed ID: 23637522 [TBL] [Abstract][Full Text] [Related]
20. Uroguanylin and guanylate cyclase C in the human pancreas: expression and mutuality of ligand/receptor localization as indicators of intercellular paracrine signaling pathways. Kulaksiz H; Cetin Y J Endocrinol; 2001 Jul; 170(1):267-75. PubMed ID: 11431160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]